Study of lisatoclax with standard chemoimmunotherapy for untreated large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called lisatoclax added to the usual chemotherapy and antibody treatment for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL). The goal is to see if adding this drug helps the standard treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL), a type of blood cancer.
- You are between 18 and 70 years old.
- You have not had any previous treatment for lymphoma.
- You have at least one tumor that can be measured or checked by scans.
- You are generally healthy enough to receive chemotherapy, with a performance status of 0 to 2 (meaning you can do most daily activities).
- You do not have lymphoma in the brain or spinal cord, active infections, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new targeted drug called birelentinib to the standard chemotherapy combination (R-CHOP) helps people with newly diagnosed aggressive lymphoma. It aims to improve the chances of remission and reduce the risk of the lymphoma coming back.
This study tests a new drug (TRS005) combined with standard chemotherapy (cyclophosphamide, doxorubicin, and prednisone) as a first treatment for people with CD20-positive DLBCL. The goal is to see if this combination is safe and effective in controlling the lymphoma.
This trial tests combining three medicines (lisaftoclax, chidamide, and rituximab) to see if they help people whose large B-cell lymphoma has returned or not responded to previous treatments. The goal is to find a new option for patients who cannot have a stem cell transplant.
This study tests whether adding a drug called trilaciclib to standard chemotherapy can help people with newly diagnosed Diffuse Large B-Cell Lymphoma. It aims to see if this combination keeps blood counts healthier and improves treatment outcomes.
This study is testing how well a new treatment works for adults who have just been diagnosed with acute lymphoblastic leukemia (ALL), a cancer of the blood and bone marrow. It aims to see if the treatment is safe and effective in helping you reach remission.
This trial tests a new combination of two targeted drugs (lisaftoclax and acalabrutinib) against standard chemo-immunotherapy for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment. It aims to see if the combination works better.
Hear when a new Diffuse Large B Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.